02.27.23
Nutritional supplement company and Certified B Corp Metagenics has named Pat Smallcombe, a current Board member and experienced industry executive, as president and CEO, effective Feb. 13. Former Metagenics President and CEO Brent Eck has accepted a new role as advisor to the Board after a 7-year tenure leading the company. Metagenics is a portfolio company of Gryphon Investors, a middle-market private equity firm.
“We are excited to welcome someone of Pat’s caliber to succeed Brent in the CEO role,” said Ryan Fagan, managing director in Gryphon’s Consumer Group. “Pat has extensive experience successfully growing consumer health businesses around the world, and his leadership will be invaluable as the company seeks to expand its already strong global footprint.”
Prior to Metagenics, Smallcombe had a long career in the consumer healthcare industry across different business models and geographic markets, including Asia, Australasia, Europe, and North America.
His most recent corporate role was serving as Company Group Chairman of EMEA for Johnson & Johnson, where he led a $3.5 billion portfolio of consumer health brands. He has also recently served as the Chairman of Sibelius Natural Products, an Oxford University spin-off that researches and develops clinically efficacious plant extracts.
“The health and wellness sector is at an inflection point, with consumers worldwide seeking greater access to innovative and proven nutritional solutions to their health concerns,” said Steve LaMonte, Metagenics Executive Chairman of the Board. “Pat is the perfect choice to help the business capitalize on the many growth opportunities it has before it.”
Smallcombe said that as a board member working with senior executives across markets and functions, “I have been able to gain a deep understanding of the strengths and opportunities ahead for Metagenics. Having begun my career as a research scientist, I have tremendous respect for the company’s science-backed heritage and believe in the organization’s commitment to improving health outcomes in partnership with healthcare practitioners.”
“We are excited to welcome someone of Pat’s caliber to succeed Brent in the CEO role,” said Ryan Fagan, managing director in Gryphon’s Consumer Group. “Pat has extensive experience successfully growing consumer health businesses around the world, and his leadership will be invaluable as the company seeks to expand its already strong global footprint.”
Prior to Metagenics, Smallcombe had a long career in the consumer healthcare industry across different business models and geographic markets, including Asia, Australasia, Europe, and North America.
His most recent corporate role was serving as Company Group Chairman of EMEA for Johnson & Johnson, where he led a $3.5 billion portfolio of consumer health brands. He has also recently served as the Chairman of Sibelius Natural Products, an Oxford University spin-off that researches and develops clinically efficacious plant extracts.
“The health and wellness sector is at an inflection point, with consumers worldwide seeking greater access to innovative and proven nutritional solutions to their health concerns,” said Steve LaMonte, Metagenics Executive Chairman of the Board. “Pat is the perfect choice to help the business capitalize on the many growth opportunities it has before it.”
Smallcombe said that as a board member working with senior executives across markets and functions, “I have been able to gain a deep understanding of the strengths and opportunities ahead for Metagenics. Having begun my career as a research scientist, I have tremendous respect for the company’s science-backed heritage and believe in the organization’s commitment to improving health outcomes in partnership with healthcare practitioners.”
